EA:NASDAQ

Electronic Arts Inc.

Data as of 2026-03-10 - not real-time

$199.27

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Electronic Arts posted a Q3 EPS of $4.82, beating the consensus, and revenue of $3.05 billion, up 37.5% YoY, highlighting strong momentum from the launch of Battlefield 6. The stock trades at a trailing PE of 74.6×, far above the industry average of 18.3×, and the DCF model values the company at roughly $130, indicating a material overvaluation at the current price of $199.27. Technicals are mixed: the 20‑day SMA (~$200.7) sits just above the market price, RSI is at 42 (neutral), and the MACD histogram is negative, suggesting short‑term bearish pressure near the support level of $197.0. Despite the price pressure, the balance sheet remains solid with $2.9 billion in cash, $2.24 billion of debt (debt‑to‑equity 36%), and a dividend yield of 0.38% supported by a payout ratio under 30%, making the dividend sustainable. The company’s beta of 0.34 and 30‑day volatility of about 10.7% point to low market sensitivity, while volume has been stable, reducing liquidity concerns. A pending merger with Silver Lake and the Public Investment Fund proposes a cash offer of $210 per share by Q1 2027, providing a clear upside catalyst. Overall, the blend of strong earnings, a premium‑priced valuation, and a merger premium creates a nuanced outlook.
Forward earnings are projected at $9.23, implying a forward PE of ~21.6×, which narrows the valuation gap but still reflects growth expectations. The company’s operating margin of 8.6% and free cash flow generation of $2.2 billion underline its ability to fund growth and returns. However, the high absolute valuation and reliance on a single merger event introduce execution risk. The gaming sector’s competitive dynamics and regulatory scrutiny remain modest, keeping sector risk at a medium level. Given these factors, investors should weigh the short‑term price pressure against the longer‑term merger upside and sustainable dividend.

Trading Recommendations

Short Term

< 1 year
hold
Conviction: 6/10

Key Factors

  • Q3 earnings beat
  • Technical bearish signals (MACD, RSI)
  • Overvaluation relative to DCF

Medium Term

1–3 years
buy
Conviction: 7/10

Key Factors

  • Merger premium at $210
  • Strong earnings momentum
  • Forward earnings improvement

Long Term

> 3 years
hold
Conviction: 6/10

Key Factors

  • Sustained dividend
  • Valuation gap vs DCF
  • Industry competitive risk

Key Metrics & Analysis

Financial Health

Revenue Growth1.00%
Profit Margin9.31%
P/E Ratio74.6
ROE10.03%
ROA4.81%
Debt/Equity36.44
P/B Ratio8.1
Op. Cash Flow$2.5B
Free Cash Flow$2.2B
Industry P/E18.3

Technical Analysis

TrendNeutral
RSI42.2
Support$197.01
Resistance$203.35
MA 20$200.70
MA 50$202.41
MA 200$183.30
MACDBearish
VolumeStable
Fear & Greed Index75.89

Valuation

Fair Value$130.16
Target Price$205.59
Upside/Downside3.17%
GradeOvervalued
TypeGrowth
Dividend Yield0.38%

Risk Assessment

Beta0.34
Volatility10.72%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies. Not financial advice. Always do your own research before making any investment decisions.